+47.5%
CCL vs MRNA
+27.9%
+19.6%
-42.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | +0.7% | -1.8% | -1.0% |
| 7D | -4.3% | -8.2% | +3.9% | -3.9% |
| 30D | -19.0% | +125.6% | -144.5% | -25.3% |
| 3M | -13.1% | +197.1% | -210.2% | -24.8% |
| 6M | -13.3% | +148.5% | -161.8% | -22.7% |
| YTD | -25.2% | +363.3% | -388.5% | -41.6% |
| 1Y | -27.2% | +462.0% | -489.2% | -45.6% |
| All | +47.5% | +27.9% | +19.6% | +21.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling